Related references
Note: Only part of the references are listed.Phase II study of topotecan in combination with dexamethasone, asparaginase, and vincristine in pediatric patients with acute lymphoblastic leukemia in first relapse
Nobuko Hijiya et al.
CANCER (2008)
Mesenchymal cells regulate the response of acute lymphoblastic leukemia cells to asparaginase
Shotaro Iwamoto et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Clinical pharmacology of asparaginases in the United States: Asparaginase population pharmacokinetic and pharmacodynamic (PK-PD) models (NONMEM) in adult and pediatric ALL patients
Vassilios I. Avramis et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2007)
Asparagine depletion after pegylated E. coli asparaginase treatment and induction outcome in children with acute lymphoblastic leukemia in first bone marrow relapse:: A children's oncology group study (CCG-1941)
Mohammad Jarrar et al.
PEDIATRIC BLOOD & CANCER (2006)
Up-regulation of asparagine synthetase expression is not linked to the clinical response to L-asparaginase in pediatric acute lymphoblastic leukemia
Inge M. Appel et al.
BLOOD (2006)
Asparagine synthetase expression is linked with L-asparaginase resistance in TEL-AML1-negative but not TEL-AML1-positive pediatric acute lymphoblastic leukemia
WAG Stams et al.
BLOOD (2005)
Pharmacokinetic/pharmacodynamic relationships of asparaginase formulations - The past, the present and recommendations for the future
VI Avramis et al.
CLINICAL PHARMACOKINETICS (2005)
Asparaginase antibody and asparaginase activity in children with higher-risk acute lymphoblastic leukemia - Children's Cancer Group Study CCG-1961
EH Panosyan et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2004)
Asparaginase pharmacokinetics after intensive polyethylene glycol-conjugated L-asparaginase therapy for children with relapsed acute lymphoblastic leukemia
DS Hawkins et al.
CLINICAL CANCER RESEARCH (2004)
Asparaginase pharmacodynamics differ by formulation among children with newly diagnosed acute lymphoblastic leukemia
LJ Hak et al.
LEUKEMIA (2004)
Lack of asparagine depletion in the cerebrospinal fluid after one intravenous dose of PEG-asparaginase: a window study at initial diagnosis of childhood ALL
JM Appel et al.
LEUKEMIA (2003)
A randomized comparison of native Escherichia coli asparaginase and polyethylene glycol conjugated asparaginase for treatment of children with newly diagnosed standard-risk acute lymphoblastic leukemia:: a Children's Cancer Group study
VI Avramis et al.
BLOOD (2002)
Multiple adaptive mechanisms affect asparagine synthetase substrate availability in asparaginase-resistant MOLT-4 human leukaemia cells
AM Aslanian et al.
BIOCHEMICAL JOURNAL (2001)
Asparagine synthetase expression alone is sufficient to induce L-asparaginase resistance in MOLT-4 human leukaemia cells
AM Aslanian et al.
BIOCHEMICAL JOURNAL (2001)
Drug monitoring of low-dose PEG-asparaginase (Oncaspar™) in children with relapsed acute lymphoblastic leukaemia
JPV Pinheiro et al.
BRITISH JOURNAL OF HAEMATOLOGY (2001)
ELISA to evaluate plasma anti-asparaginase IgG concentrations in patients with acute lymphoblastic leukemia
B Wang et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2000)
Share Paper
